Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 130

1.

Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease.

Ramlackhansingh AF, Bose SK, Ahmed I, Turkheimer FE, Pavese N, Brooks DJ.

Neurology. 2011 May 24;76(21):1811-6. doi: 10.1212/WNL.0b013e31821ccce4.

PMID:
21606452
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease.

Kase H, Aoyama S, Ichimura M, Ikeda K, Ishii A, Kanda T, Koga K, Koike N, Kurokawa M, Kuwana Y, Mori A, Nakamura J, Nonaka H, Ochi M, Saki M, Shimada J, Shindou T, Shiozaki S, Suzuki F, Takeda M, Yanagawa K, Richardson PJ, Jenner P, Bedard P, Borrelli E, Hauser RA, Chase TN; KW-6002 US-001 Study Group.

Neurology. 2003 Dec 9;61(11 Suppl 6):S97-100. Review.

PMID:
14663020
[PubMed - indexed for MEDLINE]
3.

Adenosine A(2A) receptors measured with [C]TMSX PET in the striata of Parkinson's disease patients.

Mishina M, Ishiwata K, Naganawa M, Kimura Y, Kitamura S, Suzuki M, Hashimoto M, Ishibashi K, Oda K, Sakata M, Hamamoto M, Kobayashi S, Katayama Y, Ishii K.

PLoS One. 2011 Feb 28;6(2):e17338. doi: 10.1371/journal.pone.0017338.

PMID:
21386999
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

A2A receptor antagonists do not induce dyskinesias in drug-naive or L-dopa sensitized rats.

Jones N, Bleickardt C, Mullins D, Parker E, Hodgson R.

Brain Res Bull. 2013 Sep;98:163-9. doi: 10.1016/j.brainresbull.2013.07.001. Epub 2013 Jul 6.

PMID:
23838432
[PubMed - indexed for MEDLINE]
5.

Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients.

Politis M, Wu K, Loane C, Brooks DJ, Kiferle L, Turkheimer FE, Bain P, Molloy S, Piccini P.

J Clin Invest. 2014 Mar 3;124(3):1340-9. doi: 10.1172/JCI71640. Epub 2014 Feb 17.

PMID:
24531549
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications.

Morelli M, Di Paolo T, Wardas J, Calon F, Xiao D, Schwarzschild MA.

Prog Neurobiol. 2007 Dec;83(5):293-309. Epub 2007 Jul 27. Review.

PMID:
17826884
[PubMed - indexed for MEDLINE]
7.

Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias.

Piccini P, Weeks RA, Brooks DJ.

Ann Neurol. 1997 Nov;42(5):720-6.

PMID:
9392571
[PubMed - indexed for MEDLINE]
8.

Modulation of GABAergic transmission in the striatopallidal system by adenosine A2A receptors: a potential mechanism for the antiparkinsonian effects of A2A antagonists.

Mori A, Shindou T.

Neurology. 2003 Dec 9;61(11 Suppl 6):S44-8. Erratum in: Neurology. 2004 Jan 27;62(2):348.

PMID:
14663009
[PubMed - indexed for MEDLINE]
9.

Non-dopaminergic treatments for motor control in Parkinson's disease.

Fox SH.

Drugs. 2013 Sep;73(13):1405-15. doi: 10.1007/s40265-013-0105-4. Review.

PMID:
23917951
[PubMed - indexed for MEDLINE]
10.

Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors.

Morissette M, Dridi M, Calon F, Hadj Tahar A, Meltzer LT, Bédard PJ, Di Paolo T.

Synapse. 2006 Sep 1;60(3):239-50.

PMID:
16739115
[PubMed - indexed for MEDLINE]
11.

Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias.

Calon F, Dridi M, Hornykiewicz O, Bédard PJ, Rajput AH, Di Paolo T.

Brain. 2004 May;127(Pt 5):1075-84. Epub 2004 Mar 19.

PMID:
15033896
[PubMed - indexed for MEDLINE]
Free Article
12.

Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias.

Calon F, Birdi S, Rajput AH, Hornykiewicz O, Bédard PJ, Di Paolo T.

J Neuropathol Exp Neurol. 2002 Feb;61(2):186-96.

PMID:
11853020
[PubMed - indexed for MEDLINE]
13.

Adenosine A(2A) receptor antagonist treatment of Parkinson's disease.

Bara-Jimenez W, Sherzai A, Dimitrova T, Favit A, Bibbiani F, Gillespie M, Morris MJ, Mouradian MM, Chase TN.

Neurology. 2003 Aug 12;61(3):293-6.

PMID:
12913186
[PubMed - indexed for MEDLINE]
14.

Adenosine A2A receptors in neuroadaptation to repeated dopaminergic stimulation: implications for the treatment of dyskinesias in Parkinson's disease.

Chen JF, Fredduzzi S, Bastia E, Yu L, Moratalla R, Ongini E, Schwarzschild MA.

Neurology. 2003 Dec 9;61(11 Suppl 6):S74-81.

PMID:
14663016
[PubMed - indexed for MEDLINE]
15.

Age at onset influences neurodegenerative processes underlying PD with levodopa-induced dyskinesias.

Cerasa A, Salsone M, Morelli M, Pugliese P, Arabia G, Gioia CM, Novellino F, Quattrone A.

Parkinsonism Relat Disord. 2013 Oct;19(10):883-8. doi: 10.1016/j.parkreldis.2013.05.015. Epub 2013 Jun 14.

PMID:
23769805
[PubMed - indexed for MEDLINE]
16.

Translating A2A antagonist KW6002 from animal models to parkinsonian patients.

Chase TN, Bibbiani F, Bara-Jimenez W, Dimitrova T, Oh-Lee JD.

Neurology. 2003 Dec 9;61(11 Suppl 6):S107-11. Review.

PMID:
14663022
[PubMed - indexed for MEDLINE]
17.

Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride.

Antonini A, Schwarz J, Oertel WH, Pogarell O, Leenders KL.

Mov Disord. 1997 Jan;12(1):33-8.

PMID:
8990051
[PubMed - indexed for MEDLINE]
18.

Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.

Agnati LF, Leo G, Vergoni AV, Martínez E, Hockemeyer J, Lluis C, Franco R, Fuxe K, Ferré S.

Brain Res Bull. 2004 Aug 30;64(2):155-64.

PMID:
15342103
[PubMed - indexed for MEDLINE]
19.

Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET.

Tedroff J, Pedersen M, Aquilonius SM, Hartvig P, Jacobsson G, Långström B.

Neurology. 1996 May;46(5):1430-6.

PMID:
8628494
[PubMed - indexed for MEDLINE]
20.

Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD.

Oliveri RL, Annesi G, Zappia M, Civitelli D, Montesanti R, Branca D, Nicoletti G, Spadafora P, Pasqua AA, Cittadella R, Andreoli V, Gambardella A, Aguglia U, Quattrone A.

Neurology. 1999 Oct 22;53(7):1425-30.

PMID:
10534246
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk